A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

Summary

A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

Timeline

Start

2022-10-19

Primary completion

2024-09-10

Completion

2024-09-10

Outcome

Outcome not reported

Stopped (Business): “Strategic decision”

Drugs

Indications